$20.21 Billion in Sales Expected for Johnson & Johnson (JNJ) This Quarter

Brokerages forecast that Johnson & Johnson (NYSE:JNJ) will report $20.21 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $20.07 billion and the highest is $20.62 billion. Johnson & Johnson posted sales of $18.11 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.6%. The business is expected to issue its next earnings results before the market opens on Tuesday, January 23rd.

According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $20.21 billion for the current fiscal year, with estimates ranging from $76.21 billion to $80.09 billion. For the next financial year, analysts anticipate that the company will report sales of $81.56 billion per share, with estimates ranging from $80.72 billion to $82.66 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 EPS.

A number of research firms recently weighed in on JNJ. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.40 price target on the stock in a research note on Monday. BMO Capital Markets increased their price target on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Citigroup increased their price target on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $145.52.

Several hedge funds have recently made changes to their positions in the company. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter worth about $124,000. Finally, Shine Investment Advisory Services Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth about $177,000. 65.70% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.72 on Tuesday. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $377,620.00, a price-to-earnings ratio of 24.26, a P/E/G ratio of 2.84 and a beta of 0.80.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/01/02/20-21-billion-in-sales-expected-for-johnson-johnson-jnj-this-quarter.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply